文献速递产科母胎医学

灵长类模型妊娠早期启动二甲双胍导致胎儿生物蓄积、生长受限及肾脏形态异常

Initiation of metformin in early pregnancy results in fetal bioaccumulation, growth restriction, and renal dysmorphology in a primate model.
PubMed 文献 · Am J Obstet Gynecol · 2024-06-11

本研究建立实验性灵长类模型,在确认受孕30天内给予恒河猴母体二甲双胍10 mg/kg每日两次或对照,妊娠第145天剖宫产取胎。结果显示二甲双胍在胎儿肾脏、肝脏、肠、羊水、胎盘、血清及尿中蓄积,并伴胎儿骨骼肌减少、器官质量下降及肾脏形态异常,作者认为需进一步研究产前二甲双胍的近期与远期效应。

要点

  • 妊娠早期启动二甲双胍后,药物在胎儿肾脏、肝脏、肠、羊水、胎盘、血清及尿中蓄积,胎儿水平接近母体水平。
  • 二甲双胍暴露与胎儿腓肠肌横截面积降低57%、肝脏心脏及腹膜后脂肪质量下降及出生体重降低相关(P<.05,P<.0001)。
  • 胎儿肾脏矢状切面显示成熟延迟、肾小球世代排列紊乱及皮质增厚,但无肾功能不全的结构或功能改变。

核心结论

  • 在灵长类模型中,受孕30天内母体启动二甲双胍可导致胎儿生物蓄积,并伴胎儿生长受限和肾脏形态异常。
  • 鉴于妊娠期二甲双胍使用普遍,作者认为有必要进一步研究产前二甲双胍暴露的任何近期和远期潜在效应。

研究设计与样本

  • 实验性灵长类模型研究,13只定时交配的恒河猴母体在确认受孕30天内启动每日两次人等效剂量10 mg/kg二甲双胍或赋形剂对照。
  • 母体配对饲养,喂食对照饲料或36%脂肪西式饮食,妊娠第145天剖宫产取胎,采集羊水、血、胎儿及胎盘。
  • 采用超高效液相色谱-三重四极杆质谱法直接定量母体和胎儿组织中的二甲双胍水平,并进行详细胎儿生物测量和组织病理学检查。

主要发现

  • 13例妊娠中1例赋形剂对照母体及胎儿组织可检测到二甲双胍(>1 μmol/kg母体重量或胎儿/胎盘组织),另1例赋形剂对照胎儿有严重生长受限(出生体重248.32 g,<1%)并疑似先天性疾病,2例被排除后11例纳入分析。
  • 纳分析胎儿中赋形剂对照4例(3女1男),10 mg/kg二甲双胍7例(5女2男)。
  • 二甲双胍组胎儿肾脏(0.78-6.06 μmol/kg,均值2.48 μmol/kg)、肝脏(0.16-0.73 μmol/kg,均值0.38 μmol/kg)、胎儿肠(0.28-1.22 μmol/kg,均值0.70 μmol/kg)、羊水(0.43-3.33 μmol/L,均值1.88 μmol/L)、胎盘(0.16-1.00 μmol/kg,均值0.50 μmol/kg)、胎儿血清(0.00-0.66 μmol/L,均值0.23 μmol/L)及胎儿尿(4.10-174.10 μmol/L,均值38.5 μmol/L)显著蓄积,胎儿水平接近母体水平(母血清0.18-0.86 μmol/L,均值0.46 μmol/L;母尿42.60-254.00 μmol/L,均值149.30 μmol/L)。
  • 西式饮食喂养既未加速也未减少母体或胎儿血清、尿、羊水、胎盘或胎儿组织中的二甲双胍蓄积。
  • 11例动物中,胎儿二甲双胍蓄积与腓肠肌横截面积降低57%、肝脏心脏及腹膜后脂肪质量下降相关(P<.05),共同导致分娩体重降低(P<.0001),而头臀长无变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, pragmatic metformin use in pregnancy has stretched to include prediabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus, and (most recently) preeclampsia. However, with its expanded use, concerns of unintended harm have been raised. OBJECTIVE: This study developed an experimental primate model and applied ultrahigh performance liquid chromatography coupled to triple-quadrupole mass spectrometry for direct quantitation of maternal and fetal tissue metformin levels with detailed fetal biometry and histopathology. STUDY DESIGN: Within 30 days of confirmed conception (defined as early pregnancy), 13 time-bred (timed-mated breeding) Rhesus dams with pregnancies designated for fetal necropsy were initiated on twice-daily human dose-equivalent 10 mg/kg metformin or vehicle control. Pregnant dams were maintained as pairs and fed either a control chow or 36% fat Western-style diet. Metformin or placebo vehicle control was delivered in various treats while the animals were separated via a slide. A cesarean delivery was performed at gestational day 145, and amniotic fluid and blood were collected, and the fetus and placenta were delivered. The fetus was immediately necropsied by trained primate center personnel. All fetal organs were dissected, measured, sectioned, and processed per clinical standards. Fluid and tissue metformin levels were assayed using validated ultrahigh performance liquid chromatography coupled to triple-quadrupole mass spectrometry in selected reaction monitoring against standard curves. RESULTS: Among 13 pregnancies at gestational day 145 with fetal necropsy, 1 dam and its fetal tissues had detectable metformin levels despite being allocated to the vehicle control group (>1 μmol metformin/kg maternal weight or fetal or placental tissue), whereas a second fetus allocated to the vehicle control group had severe fetal growth restriction (birthweight of 248.32 g [<1%]) and was suspected of having a fetal congenital condition. After excluding these 2 fetal pregnancies from further analyses, 11 fetuses from dams initiated on either vehicle control (n=4: 3 female and 1 male fetuses) or 10 mg/kg metformin (n=7: 5 female and 2 male fetuses) were available for analyses. Among dams initiated on metformin at gestational day 30 (regardless of maternal diet), significant bioaccumulation within the fetal kidney (0.78-6.06 μmol/kg; mean of 2.48 μmol/kg), liver (0.16-0.73 μmol/kg; mean of 0.38 μmol/kg), fetal gut (0.28-1.22 μmol/kg; mean of 0.70 μmol/kg), amniotic fluid (0.43-3.33 μmol/L; mean of 1.88 μmol/L), placenta (0.16-1.00 μmol/kg; mean of 0.50 μmol/kg), fetal serum (0.00-0.66 μmol/L; mean of 0.23 μmol/L), and fetal urine (4.10-174.10 μmol/L; mean of 38.5 μmol/L) was observed, with fetal levels near biomolar equivalent to maternal levels (maternal serum: 0.18-0.86 μmol/L [mean of 0.46 μmol/L]; maternal urine: 42.60-254.00 μmol/L [mean of 149.30 μmol/L]). Western-style diet feeding neither accelerated nor reduced metformin bioaccumulations in maternal or fetal serum, urine, amniotic fluid, placenta, or fetal tissues. In these 11 animals, fetal bioaccumulation of metformin was associated with less fetal skeletal muscle (57% lower cross-sectional area of gastrocnemius) and decreased liver, heart, and retroperitoneal fat masses (P<.05), collectively driving lower delivery weight (P<.0001) without changing the crown-rump length. Sagittal sections of fetal kidneys demonstrated delayed maturation, with disorganized glomerular generations and increased cortical thickness. This renal dysmorphology was not accompanied by structural or functional changes indicative of renal insufficiency. CONCLUSION: Our study demonstrates fetal bioaccumulation of metformin with associated fetal growth restriction and renal dysmorphology after maternal initiation of the drug within 30 days of conception in primates. Given these results and the prevalence of metformin use during pregnancy, additional investigation of any potential immediate and enduring effects of prenatal metformin use is warranted.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bolte E, Dean T, Garcia B, et al. Initiation of metformin in early pregnancy results in fetal bioaccumulation, growth restriction, and renal dysmorphology in a primate model. Am J Obstet Gynecol. 2024. PMID: 38871238. doi:10.1016/j.ajog.2024.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。